328 related articles for article (PubMed ID: 30061241)
1. Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.
Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T
Anticancer Res; 2018 Aug; 38(8):4723-4729. PubMed ID: 30061241
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
3. Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.
Tamiya M; Tamiya A; Inoue T; Kimura M; Kunimasa K; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Suzuki H; Hirashima T; Atagi S; Imamura F
PLoS One; 2018; 13(2):e0192227. PubMed ID: 29470536
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
[TBL] [Abstract][Full Text] [Related]
5. Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.
Taniguchi Y; Tamiya A; Isa SI; Nakahama K; Okishio K; Shiroyama T; Suzuki H; Inoue T; Tamiya M; Hirashima T; Imamura F; Atagi S
Anticancer Res; 2017 Oct; 37(10):5857-5862. PubMed ID: 28982912
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
Nakaya A; Kurata T; Yoshioka H; Takeyasu Y; Niki M; Kibata K; Satsutani N; Ogata M; Miyara T; Nomura S
Int J Clin Oncol; 2018 Aug; 23(4):634-640. PubMed ID: 29442281
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
Garde-Noguera J; Martin-Martorell P; De Julián M; Perez-Altozano J; Salvador-Coloma C; García-Sanchez J; Insa-Molla A; Martín M; Mielgo-Rubio X; Marin-Liebana S; Blasco-Cordellat A; Blasco-Molla S; Gironés R; Marquez-Medina D; Aparisi F; Cerda MCB; Macia-Escalante S; Sánchez A; Juan-Vidal O
Clin Transl Oncol; 2018 Aug; 20(8):1072-1079. PubMed ID: 29368144
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
Tamiya A; Tamiya M; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Inoue T; Okishio K; Nishino K; Kumagai T; Suzuki H; Hirashima T; Imamura F; Atagi S
Anticancer Res; 2017 Sep; 37(9):5199-5205. PubMed ID: 28870955
[TBL] [Abstract][Full Text] [Related]
9. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
[TBL] [Abstract][Full Text] [Related]
10. Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer.
Kataoka Y; Hirano K; Narabayashi T; Hara S; Fujimoto D; Tanaka T; Ebi N; Tomii K; Yoshioka H
Anticancer Res; 2018 Jan; 38(1):559-563. PubMed ID: 29277824
[TBL] [Abstract][Full Text] [Related]
11. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
12. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.
Pantano F; Russano M; Berruti A; Mansueto G; Migliorino MR; Adamo V; Aprile G; Gelibter A; Ficorella C; Falcone A; Russo A; Aieta M; Maio M; Martelli O; Barni S; Napolitano A; Roca E; Quadrini S; Iacono D; Russo A; Calvetti L; Occhipinti MA; Cortellini A; Vasile E; Passiglia F; Imperatori M; Calabrò L; Di Giacomo AM; Petrelli F; Pasquini G; Franchina T; Venditti O; Intagliata S; Galvano A; Fioroni I; Vincenzi B; Tonini G; Santini D
Expert Opin Biol Ther; 2020 Mar; 20(3):319-326. PubMed ID: 32011207
[No Abstract] [Full Text] [Related]
13. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
Tournoy KG; Thomeer M; Germonpré P; Derijcke S; De Pauw R; Galdermans D; Govaert K; Govaerts E; Schildermans R; Declercq I; De Brucker N; Pat K; Van Herreweghe R; Van Zandweghe L; Vanmaele L; Van Damme V; Marien H; De Craene S; Fabry I; Alexander P; Vercauter P; Demedts I
Lung Cancer; 2018 Jan; 115():49-55. PubMed ID: 29290261
[TBL] [Abstract][Full Text] [Related]
14. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.
Park W; Kwon D; Saravia D; Desai A; Vargas F; El Dinali M; Warsch J; Elias R; Chae YK; Kim DW; Warsch S; Ishkanian A; Ikpeazu C; Mudad R; Lopes G; Jahanzeb M
Clin Lung Cancer; 2018 May; 19(3):280-288.e4. PubMed ID: 29336998
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
16. Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer.
Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
Int J Clin Oncol; 2017 Aug; 22(4):690-697. PubMed ID: 28382561
[TBL] [Abstract][Full Text] [Related]
17. Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.
Dumenil C; Massiani MA; Dumoulin J; Giraud V; Labrune S; Chinet T; Giroux Leprieur E
PLoS One; 2018; 13(4):e0195945. PubMed ID: 29684049
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
Takeda T; Takeuchi M; Saitoh M; Takeda S
Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A
Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938
[TBL] [Abstract][Full Text] [Related]
20. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Tanizaki J; Haratani K; Hayashi H; Chiba Y; Nakamura Y; Yonesaka K; Kudo K; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Ito A; Nakagawa K
J Thorac Oncol; 2018 Jan; 13(1):97-105. PubMed ID: 29170120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
